Cancer News and Research

Latest Cancer News and Research

Obama's interview on health and fitness priorities to be published in a health magazine

President Barack Obama and First Lady Michelle Obama speak candidly about health and fitness priorities for the country and their family in exclusive interviews that will appear in the October 2009 issues of Men’s Health and Women’s Health, respectively. The October issues hit newsstands on Tuesday, September 15.

14 Sep 2009

Depression increases disease progression and mortality in cancer patients

Depression can affect a cancer patient's likelihood of survival. That is the finding of an analysis published in the November 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society. The results highlight the need for systematic screening of psychological distress and subsequent treatments.

14 Sep 2009

Researchers discover two proteins controlling the stem cell switch to skin cells

Scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, in collaboration with colleagues at the Centro de Investigaciones Energ-ticas, Medioambientales y Tecnologicas (CIEMAT) in Madrid, have discovered two proteins that control when and how these stem cells switch to being skin cells.

14 Sep 2009

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Nektar Therapeutics presented clinical study data today demonstrating that the oral tablet formulation of NKTR-118 has favorable systemic bioavailability and a low risk for mediating significant drug-drug interactions.

14 Sep 2009

Research data reveals why women discontinue treatment with current osteoporosis therapies

Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).

14 Sep 2009

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.

14 Sep 2009

Test for detecting ovarian cancer

The U.S. Food and Drug Administration today cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom.

14 Sep 2009

Health industry leaders optimistic on reform, though qualms remain

Industry analysts say insurers may not "have much to fear" from reform proposals, though the industry has been portrayed as "the system's main villains," the New York Times reports. Though Obama deployed several horror stories about insurers in his speech, he also said, "I have no interest in putting insurance companies out of business," and minimized the importance of the Democrat-supported, insurer-feared public health insurance plan.

11 Sep 2009

Ohio health care lobbyist pays $30,000 a year for health insurance

KHN reports on a Columbus, Ohio, health care lobbyist who writes a monthly check of $2,556 for his family's health insurance. "His insurance rates soared over the past decade after his daughter, Lauren, was diagnosed with a brain tumor and his wife, Trish, developed breast cancer.

11 Sep 2009

OCC partners with Consuelo Vanderbilt Costin to raise public awareness about ovarian cancer

The Ovarian Cancer Coalition of Greater California (OCC) has partnered with singer/songwriter/actress/philanthropist Consuelo Vanderbilt Costin for Ovarian Cancer Awareness Month, by launching a public women's health campaign for the fight against ovarian cancer.

11 Sep 2009

Accupac to manufacture Access Pharmaceuticals' MuGard

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) has entered into an agreement with a leading commercial manufacturer to produce its FDA-approved MuGard for North American distribution. One or more U.S. market seeding studies could begin as early as Q4 2009, the company says.

11 Sep 2009

University of Surrey lecturer on Co-sleeping

The event will be a series of overlapping presentations based on video clips of older people talking about their experience of poor sleep, and the impact this has on their lives. The presenters are all involved in the SomnIA (Sleep in Ageing) project based at the University of Surrey. As well as the video-based presentations and discussions, members of the audience will be invited to share some of their own experiences of poor sleep, and write down questions which they would like the panel of presenters to address during the last part of the event.

11 Sep 2009

Immigration and education policies to impact United states' leadership in science and discovery

Immigration and education policy experts gathered on Capitol Hill today to address the impact of policies related to U.S. medical innovation. The briefing, titled Education & Immigration: The Building Blocks of Innovation, was sponsored by the Council for American Medical Innovation as the first in a three-part series, Recovery Through Discovery, which examines medical innovation as a driver of U.S. economic recovery and enhanced global leadership in science.

11 Sep 2009

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

BioMarker Strategies announced today that it has raised $1.7 million in a private placement funding round that occurred in conjunction with the Maryland Biotechnology Investment Incentive Tax Credit Program. BioMarker Strategies is developing the patent-pending, SnapPath™ testing system to enable oncologists to determine the most effective drug treatment for their cancer patients.

11 Sep 2009

Genspera to commence G-202 Phase I trial following FDA approval

GenSpera, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to begin a Phase I study with its target activated pro-drug, G-202, for the treatment of cancer.

11 Sep 2009

USPTO allows Isis an additional patent for single-stranded RNAi technology

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.

11 Sep 2009

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

MN Community Measurement today announced that Regions Hospital has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a new effort to improve the quality -- and equality -- of cardiac care delivered in hospitals. The Aligning Forces for Quality: Equity Quality Improvement Collaborative (Equity QI Collaborative) will identify and test ways for hospitals to improve the quality and efficiency of their cardiac care, while also identifying and reducing any racial and ethnic disparities.

11 Sep 2009

Delcath Systems to continue Phase III clinical trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the Data and Safety Monitoring Board ("DSMB") reviewed clinical data on 77 patients enrolled in its pivotal Phase III clinical trial and unanimously recommended that the trial continue to enroll patients with the goal of reaching the 92 patients required to complete the study.

11 Sep 2009

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

The p53 tumor suppressor, a transcription factor that activates or inhibits hundreds of genes, either directly or indirectly, triggers a variety of cellular effects and plays a central role in the cellular defense against cancer. One of the main approaches for pharmacological intervention is to activate wild-type p53 in cancer cells by blocking MDM2 from binding to p53.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Cancer News and Research

Latest Cancer News and Research

Obama's interview on health and fitness priorities to be published in a health magazine

Depression increases disease progression and mortality in cancer patients

Researchers discover two proteins controlling the stem cell switch to skin cells

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Research data reveals why women discontinue treatment with current osteoporosis therapies

Phase 2 MS clinical trial data continues to show durable reductions in relapse rate

Test for detecting ovarian cancer

Health industry leaders optimistic on reform, though qualms remain

Ohio health care lobbyist pays $30,000 a year for health insurance

OCC partners with Consuelo Vanderbilt Costin to raise public awareness about ovarian cancer

Accupac to manufacture Access Pharmaceuticals' MuGard

University of Surrey lecturer on Co-sleeping

Immigration and education policies to impact United states' leadership in science and discovery

Abell Foundation plays major role in BioMarker's $1.7M private placement funding

Genspera to commence G-202 Phase I trial following FDA approval

USPTO allows Isis an additional patent for single-stranded RNAi technology

RWJF selects Regions Hospital to take part in its effort to improve cardiac care delivered in hospitals

Delcath Systems to continue Phase III clinical trial

Roche scientists use their xCELLigence System to analyze nutlin-induced apoptosis

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Cancer Research - Second Edition eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in